Stockscreener 앱 받기
8.10
1.89%
0.15
Ensysce Biosciences Inc 주식(ENSC)의 최신 뉴스
Ensysce Biosciences (NASDAQ:ENSC) Stock Quotes, Forecast and News Summary - Benzinga
Ensysce Biosciences Secures Critical Supply Deal for Breakthrough Overdose Protection Drug Development - StockTitan
983,518 Shares in Ensysce Biosciences, Inc. (NASDAQ:ENSC) Bought by Anson Funds Management LP - MarketBeat
ENSC Stock Touches 52-Week High at $7.24 Amid Market Volatility - Investing.com Nigeria
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Announces Enrollment Completion for PF614-201 Clinical Study - Marketscreener.com
Revolutionizing Pain Relief: The next generation of opioids | Interview with Ensysce Biosciences CEO - Marketscreener.com
Ensysce Biosciences, Inc. Announces Investigational Review Board Approval of Key Study Protocol - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Announces Completion of Site Initiation Visit for PF614-201 Clinical Study - Marketscreener.com
Ensysce Biosciences, Inc. Announces Key Efficacy Data for Lead Analgesic - Marketscreener.com
Ensysce Biosciences, Inc. Submits Phase 3 Protocol to the FDA - Marketscreener.com
Ensysce Biosciences Shares Up 39% on FDA Breakthrough Designation for PF614-MPAR - Marketscreener.com
Ensysce Biosciences, Inc. Announces Strategic Partnership for the Development and Commercial Launch of Pf614 and Pf614-Mpar - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Ensysce Biosciences, Inc. Announces Renewal of Collaboration with Quotient Sciences to Undertake the Study PF614-MPAR-102 to Examine and Evaluate the Full Commercial Dose Range of the PF614-MPAR Drug Product - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Ensysce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ensysce Biosciences Lands $10M Strategic Manufacturing Deal for Novel Pain Relief Pipeline - StockTitan
Ensysce Biosciences announces reverse stock split By Investing.com - Investing.com UK
Ensysce Biosciences Announces 1-for-15 Reverse Stock Split to Maintain Nasdaq Listing - StockTitan
Ensysce Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 - Marketscreener.com
Ensysce Biosciences Launches Key Trial for Breakthrough Opioid Drug, Backed by $14M NIDA Grant | ENSC Stock News - StockTitan
Anson Funds Management LP Acquires New Stake in Ensysce Bioscien - GuruFocus.com
Ensysce Biosciences Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate - Simply Wall St
Comparing Ensysce Biosciences (NASDAQ:ENSC) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) - Defense World
Ensysce Biosciences, Inc. (NASDAQ:ENSC) Short Interest Up 5,514.5% in October - Defense World
Ensysce Biosciences Reports Improved Financial Results - TipRanks
Ensysce Biosciences Reports Third Quarter 2024 Financial Results - AccessWire
Ensysce Biosciences Secures $14M NIH Grant, Swings to Q3 Profit Amid Clinical Progress | ENSC Stock News - StockTitan
Ensysce Biosciences granted Nasdaq listing extension By Investing.com - Investing.com Canada
Ensysce Biosciences granted Nasdaq listing extension - Investing.com
Ensysce Biosciences Receives Positive Nasdaq Listing Determination - AccessWire
Ensysce Biosciences Secures Critical Nasdaq Extension Through 2024 Amid Listing Challenges | ENSC Stock News - StockTitan
RA Capital Management, L.P. Acquires New Stake in Ensysce Biosci - GuruFocus.com
Ensysce Biosciences (NASDAQ:ENSC) Trading Down 9.8% – What’s Next? - Defense World
Ensysce Biosciences Presenting at Upcoming Meetings - GuruFocus.com
Dow Surges Over 150 Points; Alphabet Posts Upbeat ResultsAlphabet (NASDAQ:GOOGL) - Benzinga
Perceptive Advisors LLC's Strategic Acquisition of Ensysce Biosc - GuruFocus.com
3 Penny Stocks to Watch Now, 10/24/24 - TipRanks
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving PremarketStride (NYSE:LRN) - Benzinga
Regeneron Pharmaceuticals (REGN) Stock Drops Amid Market Volatility - GuruFocus.com
Advaxis (ADXS) Sees 112.96% Surge Amid Market Volatility - GuruFocus.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Ensysce Biosciences adjusts quorum requirement for stockholder meetings - Investing.com India
Ensysce Biosciences adjusts quorum requirement for stockholder meetings By Investing.com - Investing.com South Africa
When Will Ensysce Biosciences, Inc. (NASDAQ:ENSC) Breakeven? - Simply Wall St
Ensysce Biosciences Inc (ENSC) presents a great opportunity, but the stock is slightly undervalued - US Post News
2.88%
2.65%
자본화:
|
볼륨(24시간):